Pharmacokinetic Study of Raltegravir in Human Immunodeficiency Virus/Hepatitis C Virus (HIV/VHC) Coinfected Patients With Advanced (Child-Pugh C) Hepatic Cirrhosis (LIVERAL)
Phase I, Open Label, Unicentric Study of Multiple-dose Pharmacokinetics of Raltegravir in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus With and Without Advanced (Child-Pugh C) Hepatic Cirrhosis.
Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Listed as NCT01289951, this PHASE1 trial focuses on Hepatitis C and Human Immunodeficiency Virus and remains completed. Sponsored by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal, it has been updated 6 times since 2010, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jun 2022 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Dec 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .